How a Common Blood Pressure Drug Helps Stroke Survivors Reach a Critical Health Target
Testing an added medication
The REDUCE trial examined whether spironolactone could help people whose blood pressure remained high after a stroke. Researchers compared the medication, added to standard post-stroke care, with usual care alone.
Participants monitored their blood pressure at home over six months. The findings were presented at the American Heart Association's Scientific Sessions in Chicago, held Nov. 6-9, 2026.
Blood pressure results
After three months, the average top blood pressure reading was nearly eight points lower for people taking spironolactone: about 126, compared with 133 for those receiving usual care. The recommended blood pressure goal is below 130/80. Fifty-two percent of participants taking spironolactone reached it, compared with 30% in the usual-care group.
Researchers urge caution
Cohen said the drop seen when spironolactone was added to post-stroke care may reduce the risk of future strokes and heart attacks. Dr. Alfred Joshua, an emergency physician in California who was not involved in the research, called the findings encouraging but said they do not show that the medication prevents a subsequent stroke.
Key points
- Spironolactone was tested as an addition to routine care after a stroke.
- After three months, the average top blood pressure reading was about 126 with spironolactone and 133 with usual care.
- Fifty-two percent of participants taking the drug reached below 130/80, versus 30% receiving usual care.
- The findings do not establish that spironolactone prevents another stroke.